Research Article

Effects of Mentha suaveolens Essential Oil on Chlamydia trachomatis

Rosa Sessa,1 Marisa Di Pietro,1 Fiorenzo De Santis,1 Simone Filardo,1 Rino Ragno,2 and Letizia Angiolella1

1Department of Public Health and Infectious Diseases, “Sapienza” University, Piazzale Aldo Moro 5, 00185 Rome, Italy
2Department of Drugs Chemistry and Technology, “Sapienza” University, Piazzale Aldo Moro 5, 00185 Rome, Italy

Correspondence should be addressed to Rosa Sessa; rosa.sessa@uniroma1.it

Received 30 July 2014; Accepted 13 October 2014

Academic Editor: György Schneider

Copyright © 2015 Rosa Sessa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chlamydia trachomatis, the most common cause of sexually transmitted bacterial infection worldwide, has a unique biphasic developmental cycle alternating between the infectious elementary body and the replicative reticulate body. C. trachomatis is responsible for severe reproductive complications including pelvic inflammatory disease, ectopic pregnancy, and obstructive infertility. The aim of our study was to evaluate whether Mentha suaveolens essential oil (EOMS) can be considered as a promising candidate for preventing C. trachomatis infection. Specifically, we investigated the in vitro effects of EOMS towards C. trachomatis analysing the different phases of chlamydial developmental cycle. Our results demonstrated that EOMS was effective towards C. trachomatis, whereby it not only inactivated infectious elementary bodies but also inhibited chlamydial replication. Our study also revealed the effectiveness of EOMS, in combination with erythromycin, towards C. trachomatis with a substantial reduction in the minimum effective dose of antibiotic. In conclusion, EOMS treatment may represent a preventative strategy since it may reduce C. trachomatis transmission in the population and, thereby, reduce the number of new chlamydial infections and risk of developing of severe sequelae.

1. Introduction

Chlamydia trachomatis, an obligate intracellular pathogen, is the leading cause of bacterial sexually transmitted diseases in the world with an estimated over 105 million new cases every year [1]. It manifests as cervicitis, salpingitis, and endometritis and can be transmitted to infants during delivery resulting in neonatal conjunctivitis and pneumonitis [2]. Chlamydial genital infections have also been reported to increase human immunodeficiency virus (HIV) transmission [2, 3] and influence the development of human papilloma virus induced adenocarcinoma [2, 4].

A major concern with chlamydial genital infections is that approximately 80% of women are asymptomatic, thus resulting in a reservoir for onwards transmission in the population. Consequently, C. trachomatis untreated infections can progress leading to chronic severe sequelae, including pelvic inflammatory disease, ectopic pregnancy, and obstructive infertility [2].

Similarly to C. trachomatis, Chlamydia pneumoniae has also been associated with several chronic diseases such as atherosclerosis, Alzheimer’s disease, asthma, and more recently osteoporosis-related bone loss [5–7].

Several studies have suggested that the development of Chlamydiaceae associated chronic diseases may be related to the persistent form that can arise under stressful growth conditions imposed, for example, by antibiotic treatment and herpes simplex virus type 2 (HSV-2) coinfection [8, 9].

C. trachomatis has an intriguing and unique biphasic developmental cycle alternating between the extracellular, infectious, metabolically inactive elementary body (EB) and the intracellular, noninfectious, metabolically active reticulate body (RB). Apart from EB and RB, a third nonreplicating and noninfectious form, called persistent form, has been described to be responsible for establishing chronic infections since they are able to evade the host immune response and are more difficult to eradicate by antibiotics [8].
The existence of *C. trachomatis* EBs and RBs as well as the persistent forms makes the treatment of infection a challenge. Beta-lactam antibiotics, commonly used against bacterial infections because they are able to inhibit the peptidoglycan synthesis, are ineffective towards *C. trachomatis* for the lack of a classical peptidoglycan [10], and some of them such as penicillin G are even able to induce persistent forms [8, 9].

In contrast, macrolides including azithromycin and erythromycin appear to be effective against *C. trachomatis* [11] although several clinical treatment failures have been reported [12, 13]. The major cause for *C. trachomatis* therapeutic failure may be chlamydial resistance to antibiotic [14–16]. In addition, the phenomenon of antibiotic resistance in *C. trachomatis* could be more complex since it may be also related to the development of persistent forms [17].

Thus, given the impact of asymptomatic chlamydial infections on reproductive outcomes as well as the emerging resistance of *C. trachomatis* to antibiotics and the risk of developing persistent forms, preventing new infections becomes a priority.

Recently, a great interest in natural products as alternative treatment for preventing infections has been raised in view of their extensive biological effects including anticancer, antioxidant, and other pharmacological activities [18]. Essential oils derived from aromatic medicinal plants, such as *Mentha* species, have been explored and gained prominence; in previous studies, it has been demonstrated that *Mentha suaveolens* essential oil was effective against yeasts, fungi, and viruses [19–24].

Therefore, the aim of our study was to evaluate whether *Mentha suaveolens* essential oil can be considered as a promising candidate for preventing *C. trachomatis* genital infections. Specifically, we investigated the in vitro effects of *Mentha suaveolens* essential oil on the lymphogranuloma venereum strain of *C. trachomatis* analysing the different phases of chlamydial developmental cycle.

2. Materials and Methods

2.1. Essential Oil. *Mentha suaveolens* essential oil (EOMS) was obtained from wild-type plants grown in Tarquinia forests (Rome, Italy) and was extracted by 4 h hydrodistillation of the aerial parts using a Clevenger-type apparatus as previously described. After 48 h of incubation at 37 °C and 5% CO₂, fixed with methanol, and stained with fluorescein isothiocyanate conjugated monoclonal (FITC) antibody against *C. trachomatis* MOMP (Micro-Trak *Chlamydia trachomatis* Culture Confirmation Test, Trinity Biotech, USA). The total number of IFUs was enumerated by counting all microscope fields using a fluorescence microscope (400x magnification).

2.2. Propagation and Titration of *C. trachomatis*. *C. trachomatis* lymphogranuloma venereum (LGV) serovar L2 (ATCC VR-902B) was propagated in HeLa cells (ATCC CCL-2) grown in 6-well plates (1 × 10⁵ cells/well) in Dulbecco’s Modified Eagle’s medium (DMEM, Euroclone, Italy) high glucose supplemented with 10% heat inactivated foetal calf serum (FCS, Euroclone, Italy). Infected HeLa cells were centrifuged at 900 × g for 60 min at 37 °C. The supernatant was removed and replaced with DMEM high glucose supplemented with 10% FCS, 10 mM HEPES (Sigma-Aldrich, St. Louis, USA), and 1 μg/mL cycloheximide (Sigma-Aldrich, St. Louis, USA). After 48 h of incubation at 37 °C and 5% CO₂, infected cells were harvested in sucrose-phosphate-glutamate buffer (SPG buffer) (0.2 M sucrose, 3.8 mM KH₂PO₄, 6.7 mM Na₂HPO₄, and 5.5 mM glutamic acid at pH 7.4) and vortexed with sterile glass beads for 2–5 min. After removal of cell debris by centrifugation at 250 × g for 10 min, the supernatant was centrifuged at 20,000 × g and 4°C for 20 min and the pellet, resuspended in SPG buffer, was stored at −70°C.

The infectious titre (inclusion-forming units (IFU)/mL) was assessed by immunofluorescence assay. Briefly, HeLa cells (2 × 10⁵ cells/well), grown on glass coverslips in 24-well plates, were infected with tenfold serial dilutions of chlamydial EBs suspension, incubated for 48 h at 37°C and 5% CO₂, fixed with methanol, and stained with fluorescein isothiocyanate conjugated monoclonal (FITC) antibody against *C. trachomatis* MOMP (Micro-Trak *Chlamydia trachomatis* Culture Confirmation Test, Trinity Biotech, USA). The total number of IFUs was enumerated by counting all microscope fields using a fluorescence microscope (400x magnification).

2.3. Cytotoxicity Assay. The cytotoxicity of EOMS was determined on HeLa cells using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Briefly, 1.0 × 10⁴ HeLa cells were seeded in 96-well plates and incubated, at 37°C and 5% CO₂, with twofold serial dilutions of EOMS (2 mg/mL–16 μg/mL in DMEM) for 1 or 48 h (the cells incubated for 1 h were washed with PBS and further incubated in fresh medium). After 48 h incubation, HeLa cells were incubated with MTT reagent (5 mg/mL) for 4 h. Afterwards, the medium was removed and formazan crystals were dissolved with the MTT solubilisation solution (0.1 N HCl in isopropanol). The amount of formazan produced was detected by measuring the absorbance at 570 nm (ELISA reader). CC50 was defined as the product concentration required for reducing the cell viability by 50%.

2.4. Effect of EOMS towards Chlamydial EBs. Chlamydial EBs at a multiplicity of infection (MOI) of 0.05 IFU/cell were incubated in the presence or absence of EOMS for 30, 60, or 120 min at 37°C and 5% CO₂. After the incubation period, the mixture containing chlamydial EBs and EOMS was diluted 1:100 in DMEM and used to infect HeLa cell monolayers grown in 24-well plates (2 × 10⁵ cells/well), as previously described. After 48 h of incubation at 37°C and 5% CO₂ in cycloheximide-free medium, infected and treated cells were recovered to determine the infectivity yield and the IC₅₀ value.

2.5. Effect of EOMS on *C. trachomatis* Replication. HeLa cell monolayers (2 × 10⁵ cells/well) grown in 24-well plates were infected with *C. trachomatis* (MOI 0.05) by centrifugation at 900 × g at 37°C for 1 h. After removal of chlamydial inoculum, infected HeLa cells were incubated with twofold serial dilutions of EOMS prepared in culture medium. After 48 h of incubation at 37°C and 5% CO₂ in cycloheximide-free medium, infected and treated cells were recovered to determine the infectivity yield and the IC₅₀ value.
2.6. Effect of EOMS on Different Phases of Chlamydial Infection. EOMS was added during different phases of *C. trachomatis* infection as follows: (A) chlamydial EBs suspension was preincubated with EOMS for 2 h; (B) HeLa cells, grown in 24-well plates (2.0 × 10⁵ cells/well), were preincubated with EOMS for 2 h; (C) EOMS was added during *C. trachomatis* infection; and (D) EOMS was added during the 48 h postinfection period.

In all conditions, cells were incubated at 37°C and 5% CO₂ in cycloheximide-free medium. After 48 h of incubation, infected and treated cells were recovered to determine the infectivity yield and the IC₅₀ value.

2.7. Effect of EOMS in Combination with Erythromycin. HeLa cell monolayers (2.0 × 10⁵ cells/well) grown in 24-well plates were infected with *C. trachomatis* (MOI 0.05) by centrifugation at 900 × g at 37°C for 1 h. After removal of chlamydial inoculum, infected HeLa cells were incubated with different concentrations of erythromycin (0.008–0.5 μg/mL). After 48 h incubation at 37°C and 5% CO₂ in cycloheximide-free medium, infected and treated cells were recovered and used to determine the infectivity yield and the IC₅₀ value.

The combined effect between EOMS and erythromycin was assessed after infection of HeLa cells with *C. trachomatis* (MOI 0.05) as above described. Following removal of chlamydial inoculum, HeLa cells monolayers were treated with EOMS and subinhibitory doses of erythromycin. After 48 h of incubation at 37°C and 5% CO₂ in cycloheximide-free medium, infected and treated cells were recovered to determine the infectivity yield and the IC₅₀ value.

2.8. Assessment of Infectivity Yield. Infectivity yield was determined by the development of inclusions after passage to fresh HeLa cell monolayers. Briefly, cell monolayers were disrupted and repassed onto fresh HeLa cell monolayers grown on glass coverslips in 24 well-plates. After 48 h of incubation at 37°C and 5% CO₂, the total number of *C. trachomatis* IFUs was counted by immunofluorescence assay.

The product concentration required to reduce chlamydial infectivity yield by 50% was defined as IC₅₀.

2.9. Statistical Analysis. All values are expressed as mean ± standard deviation (SD) of three replicates from three independent experiments. Comparison of means was performed by using a two-tailed t-test for independent samples. A value of *P* < 0.05 was considered statistically significant.

3. Results

3.1. Cytotoxicity of EOMS. In order to assess the cytotoxic effect of EOMS, HeLa cell monolayers were incubated with increasing concentrations of essential oil for 1 h or 48 h and, then, cell viability was measured by the MTT assay.

No significant cytotoxicity was observed following 1 h exposure of EOMS up to 500 μg/mL (Figure 1). The CC₅₀ of EOMS was 1000 μg/mL.

3.2. Effect of EOMS on Chlamydial EBs. In order to determine whether EOMS was active against chlamydial EBs, twofold serial dilutions of essential oil (from 1000 μg/mL to 125 μg/mL) were incubated with the EBs suspension for different periods. As shown in Figure 2, exposure of chlamydial EBs to concentrations of EOMS greater than 125 μg/mL resulted in the inhibition of chlamydial infection as evidenced by a significant reduction in infectivity yield after 60 min of treatment as compared to infected cells alone (*P* = 0.04). A more marked reduction in infectivity yield was observed when the chlamydial EBs suspension was treated with 500 μg/mL EOMS for 30, 60, or 120 min as compared to infected cells alone (*P* = 0.004; *P* = 0.003; and *P* = 0.003); a higher reduction in infectivity yield was observed in infected and treated cells for 60 or 120 min as compared to infected and treated cells for 30 min (30 min versus 60 min, *P* = 0.01; 30 min versus 120 min, *P* = 0.008). Again, a higher reduction...
in infectivity yield was observed in infected and treated cells for 120 min as compared to infected and treated cells for 60 min ($P = 0.02$).

Chlamydial EBs were completely inactivated following exposure to 1000 μg/mL EOMS for 30 min (Figure 2).

The IC$_{50}$ value for EOMS was 500 μg/mL after 30 min of incubation whereas it was reduced to 250 μg/mL after 60 and 120 min of incubation.

### 3.3. Effect of EOMS on C. trachomatis Replication

The effect of EOMS on C. trachomatis replication was evaluated by treating infected cells with increasing concentrations of essential oil. EOMS at a concentration of 32 μg/mL inhibited the chlamydial replication as evidenced by a significant reduction in infectivity yield observed in infected and treated cells as compared to infected cells alone ($P = 0.002$). EOMS was more effective in inhibiting C. trachomatis at a concentration of 64 μg/mL ($P = 0.004$). A higher inhibitory effect of EOMS on C. trachomatis was observed in cells treated with 64 μg/mL as compared to cells treated with 32 μg/mL ($P = 0.025$) (Figure 3). The IC$_{50}$ value of EOMS was 32 μg/mL.

Interestingly, the sizes of individual chlamydial inclusions in cells infected and treated with EOMS were much smaller than those of infected cells alone, although it was not quantified. The effect of EOMS in chlamydial inclusion size reduction was dose dependent. Indeed, chlamydial inclusions from cells treated with 64 μg/mL were much smaller as compared to those from cells treated with 32 μg/mL (Figure 4).

Based on the best inhibitory effect towards C. trachomatis and the absence of cytotoxicity of EOMS at 64 μg/mL we used this concentration to determine more specifically which phase of chlamydial infection was impaired by the essential oil. The treatment conditions included pretreatment of chlamydial EBs suspension for 2 h, the pretreatment of host cells for 2 h, the coinubcation of EOMS and C. trachomatis with host cells, and the addition of EOMS during the C. trachomatis postinfection period of 48 h. As shown in Figure 5, a significant reduction in infectivity yield was observed when EOMS was added during the 48 h postinfection phase as compared to infected cells alone ($P = 0.002$).

### 3.4. Effect of EOMS in Combination with Erythromycin

We first determined the activity of erythromycin towards C. trachomatis by treating infected cells with different concentrations of antibiotic (0.008–0.5 μg/mL) for 48 h. The IC$_{50}$ of the erythromycin was 0.030 μg/mL, and at a concentration of 0.064 μg/mL the chlamydial replication was completely inhibited.

Next, we evaluated the effects of EOMS in combination with erythromycin towards C. trachomatis by treating infected cells with 64 μg/mL EOMS and subinhibitory doses of erythromycin. Erythromycin in combination with EOMS completely inhibited C. trachomatis replication at a concentration of 0.016 μg/mL with IC$_{50}$ of 0.007 μg/mL.

### 4. Discussion

C. trachomatis is a significant public health problem because of the impact of asymptomatic infections on reproductive outcomes, the transmission of other sexually acquired agents, and the severe sequelae associated with the persistent forms. Indeed, in women, up to 40% of C. trachomatis untreated infections progress to serious complications [2], and there is also the evidence that an existing chlamydial genital infection may increase the risk of acquiring HSV-2 [25] and HIV [2, 3]. In particular, in the presence of sexually transmitted diseases including C. trachomatis infection the risk of HIV transmission may increase by three- to tenfold [26].

Lastly, C. trachomatis persistent forms are of particular clinical importance considering that they seem to be involved in the pathogenesis of adverse reproductive consequences of C. trachomatis infection since they may act as chronic stimuli leading to chronic inflammatory state and subsequent tissue damage [27].

In our study, we evaluated the activity of EOMS towards C. trachomatis in view of its safety and beneficial effect in topical treatment of vaginal candidiasis [28]. In particular, we investigated the aggressive LGV serovar of C. trachomatis known for its increasing incidence in Western Europe and North America [29, 30] and for its association with increased risk of HIV acquisition in several underdeveloped countries [31, 32].

Our results demonstrated that EOMS was not cytotoxic to epithelial cell line as was also evidenced in other studies [23, 28] and it was effective against C. trachomatis. Specifically, EOMS had a direct effect on chlamydial infectious EBs as shown by the significant reduction in infectivity yield observed after treatment of EBs with essential oil (IC$_{50}$: 500 μg/mL, 30 min). It is likely that EOMS inactivates EBs by disrupting lipid bilayers or by interfering with chlamydial components, which are essential for the entry into host cells, a fundamental stage in chlamydial infection cycle and pathogenesis.

In addition to inhibiting chlamydial EBs, EOMS was also effective after entry of C. trachomatis into host cells as shown by the significant reduction in infectivity yield after 48 h of treatment (IC$_{50}$: 32 μg/mL). Such effect was also demonstrated by the decreased size of individual chlamydial inclusions observed in infected and treated cells as compared...
Figure 4: Immunohistological staining of *C. trachomatis* infected cell monolayers in the presence or absence of EOMS. HeLa cell monolayers were infected with *C. trachomatis* (MOI 0.05) and incubated in the presence ((a) 16 μg/mL; (b) 32 μg/mL; and (c) 64 μg/mL) or absence of EOMS (d). After 48 h of incubation, HeLa cell monolayers were fixed, stained, and visualised by fluorescence microscopy (400x magnification). Bars: 50 μm.

Figure 5: Effects of EOMS (64 μg/mL) on different phases of *C. trachomatis* infection. (A) chlamydial EBs pretreatment with EOMS for 2 h. (B) HeLa cell monolayer pretreatment with EOMS for 2 h. (C) Addition of EOMS during chlamydial infection. (D) Addition of EOMS during postinfection period. After 48 h of incubation, treated and untreated HeLa cell monolayers were recovered to determine the chlamydial infectivity yield. *P < 0.05* versus untreated cells.

The inhibitory effect of EOMS on chlamydial replication was further corroborated by the observation that early stages of *C. trachomatis* developmental cycle including the adhesion and the entry into host cell were not impaired by EOMS treatment.

As known, the management and control of *C. trachomatis* infection become increasingly challenging. Currently, erythromycin and azithromycin are recommended for treating *C. trachomatis* infections although these drugs have been shown to have side effects [33, 34]. In this regard, a particularly interesting finding of our study was the effectiveness of EOMS in combination with erythromycin against *C. trachomatis* with a considerable fourfold reduction in the minimum effective dose of antibiotic. The combination of EOMS antibiotic has shed light on a novel approach in controlling *C. trachomatis* infection and in decreasing the adverse effects of antibiotics. Limiting the effective dose of antibiotic reduces also the costs in financial terms since the combination of existing drugs require less costs than developing new drugs.

Thus, EOMS is effective towards *C. trachomatis* by several ways. First, EOMS inactivates *C. trachomatis* EBs supposedly preventing the entry in host cell, key phase for establishing the infection. Second, EOMS inhibits *C. trachomatis* replication reducing the infectivity and hence the progression of infection. Third, EOMS in combination with erythromycin inhibits *C. trachomatis* replication reducing the minimum effective dose of the antibiotic.

5. Conclusion

The present study revealed, for the first time, that EOMS was effective towards *C. trachomatis* by inactivating infectious elementary bodies and inhibiting chlamydial replication. These findings suggest that EOMS treatment may represent...
a preventative strategy for reducing *C. trachomatis* transmission in the population, the number of new chlamydial infections, and the risk of developing severe sequelae, even if further studies on the activity of EOMS towards vaginal bacterial flora and other sexually acquired agents are needed.

**Conflict of Interests**

The authors have declared that no conflict of interests exists.

**Acknowledgment**

This study was supported by grants from Center for Social Disease Research, "Sapienza" University of Rome, to Rosa Sessa.

**References**

[1] World Health Organization, *Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections Overview and Estimates*, WHO, Geneva, Switzerland, 2008, http://apps.who.int/iris/bitstream/10665/75181/1/9789241503839_eng.pdf?ua=1.

[2] K. Shaw, D. Coleman, M. O’Sullivan, and N. Stephens, "Public health policies and management strategies for genital *Chlamydia trachomatis* infection," *Risk Manag Healthc Policy*, vol. 4, pp. 55–65, 2011.

[3] S. Bhattar, P. Bhalla, S. Chadha, R. Tripathi, R. Kaur, and K. Sardana, "*Chlamydia trachomatis* infection in HIV-infected women: need for screening by a sensitive and specific test," *Infectious Diseases in Obstetrics and Gynecology*, vol. 2013, Article ID 960769, 6 pages, 2013.

[4] J. Silva, F. Cerqueira, and R. Medeiros, "*Chlamydia trachomatis* infection: implications for HPV status and cervical cancer," *Archives of Gynecology and Obstetrics*, vol. 289, no. 4, pp. 715–723, 2014.

[5] M. di Pietro, G. Schiavoni, V. Sessa, F. Pallotta, G. Costanzo, and R. Sessa, "*Chlamydia pneumoniae* and osteoporosis-associated bone loss: a new risk factor?" *Osteoporosis International*, vol. 24, no. 5, pp. 1677–1682, 2013.

[6] M. Di Pietro, S. Filardo, F. De Santis, and R. Sessa, "*Chlamydia pneumoniae* infection in atherosclerotic lesion development through oxidative stress: a brief overview," *International Journal of Molecular Sciences*, vol. 14, no. 7, pp. 15105–15120, 2013.

[7] S. Orrskog, E. Medin, S. Tsolova, and J. C. Semenza, "Causal inference regarding infectious aetiology of chronic conditions: a systematic review," *PLoS ONE*, vol. 8, no. 7, Article ID e68861, 2013.

[8] P. B. Wyrick, "*Chlamydia trachomatis* persistence in vitro: an overview," *The Journal of Infectious Diseases*, vol. 201, no. 2, pp. 588–595, 2010.

[9] M. di Pietro, A. Tramonti, F. de Santis et al., "Analysis of gene expression in penicillin G induced persistence of *Chlamydia pneumoniae*," *Journal of Biological Regulators and Homeostatic Agents*, vol. 26, no. 2, pp. 277–284, 2012.

[10] M. Di Pietro, F. de Santis, D. di Biase, and R. Sessa, "The elusive but pathogenic peptidoglycan of *Chlamydia*," *European Journal of Inflammation*, vol. 11, no. 1, pp. 257–260, 2013.

[11] M. R. Hammerschlag and S. A. Kohlhoff, "Treatment of chlamydial infections," *Expert Opinion on Pharmacotherapy*, vol. 13, no. 4, pp. 545–552, 2012.

[12] J. A. Schillinger, P. Kissinger, H. Calvet et al., "Patient-delivered partner treatment with azithromycin to prevent repeated *Chlamydia trachomatis* infection among women: a randomized, controlled trial," *Sexually Transmitted Diseases*, vol. 30, no. 1, pp. 49–56, 2003.

[13] J. S. Hocking, L. A. Vodstrcil, W. M. Huston et al., "A cohort study of *Chlamydia trachomatis* treatment failure in women: a study protocol," *BMC Infectious Diseases*, vol. 13, no. 1, article 379, 2013.

[14] J. Somani, V. B. Bhullar, K. A. Workowski, C. E. Farshy, and C. M. Black, "Multiple drug-resistant *Chlamydia trachomatis* associated with clinical treatment failure," *The Journal of Infectious Diseases*, vol. 181, no. 4, pp. 1421–1427, 2000.

[15] O. Y. Misyurina, E. V. Chipitsyna, Y. P. Finashutina et al., "Mutations in a 23S rRNA gene of *Chlamydia trachomatis* associated with resistance to macrolides," *Antimicrobial Agents and Chemotherapy*, vol. 48, no. 4, pp. 1347–1349, 2004.

[16] A. R. Bhengraj, H. Vardhan, P. Srivastava, S. Salhan, and A. Mittal, "Decreased susceptibility to azithromycin and doxycycline in clinical isolates of *Chlamydia trachomatis* obtained from recurrently infected female patients in India," *Chemotherapy*, vol. 56, no. 5, pp. 371–377, 2010.

[17] U. Dreeses-Werringloer, I. Padubrin, H. Zeidler, and L. Köhler, "Effects of azithromycin and rifampin on *Chlamydia trachomatis* infection in vitro," *Antimicrobial Agents and Chemotherapy*, vol. 45, no. 11, pp. 3001–3008, 2001.

[18] W. Ding, J. Gu, L. Cao et al., "Traditional Chinese herbs as chemical resource library for drug discovery of anti-infective and anti-inflammatory," *Journal of Ethnopharmacology*, vol. 155, no. 1, pp. 589–598, 2014.

[19] H. Oumzil, S. Ghoulami, M. Rhajaoui et al., "Antibacterial and antifungal activity of essential oils of *Mentha suaveolens*," *Phytotherapy Research*, vol. 16, no. 8, pp. 727–731, 2002.

[20] N. Mimica-Dukić, B. Božin, M. Soković, B. Mihajlović, and M. Matavulj, "Antimicrobial and antioxidant activities of three *Mentha* species essential oils," *Planta Medica*, vol. 69, no. 5, pp. 413–419, 2003.

[21] L. Angiolella, E. Valava, S. Sivirc, D. F. Diodata, and R. Rago, "In vitro activity of *Mentha suaveolens* essential oil against *Cryptococcus neoformans* and dermatophytes," *International Journal of Essential Oil Therapeutics*, vol. 4, no. 1-2, pp. 35–36, 2010.

[22] L. Civitelli, S. Panella, M. E. Marcocci et al., "In vitro inhibition of herpes simplex virus type 1 replication by *Mentha suaveolens* essential oil and its main component piperitenone oxide," *Phytomedicine*, vol. 21, no. 6, pp. 857–865, 2014.

[23] A. Stringaro, E. Valava, M. Colone et al., "Effects of *Mentha suaveolens* essential oil alone or in combination with other drugs in *Candida albicans*," *Evidence-Based Complementary and Alternative Medicine*, vol. 2014, Article ID 125904, 9 pages, 2014.

[24] A. Astani, M. Heidary Navid, and P. Schnitzler, "Attachment and penetration of acyclovir-resistant herpes simplex virus are inhibited by *Melissa officinalis* extract," *Phytotherapy Research*, vol. 28, no. 10, pp. 1547–1552, 2014.

[25] P. Mastromarino, M. Di Pietro, G. Schiavoni, C. Nardis, M. Gentile, and R. Sessa, "Effects of vaginal lactobacilli in *Chlamydia trachomatis* infection," *International Journal of Medical Microbiology*, vol. 304, no. 5-6, pp. 654–661, 2014.

[26] L. C. F. Silva, A. E. Miranda, R. S. Batalha et al., "*Chlamydia trachomatis* infection among HIV-infected women attending an AIDS clinic in the city of Manaus, Brazil," *Brazilian Journal of Infectious Diseases*, vol. 16, no. 4, pp. 335–338, 2012.
[27] R. B. Ness, D. E. Soper, H. E. Richter et al., “Chlamydia antibodies, chlamydia heat shock protein, and adverse sequelae after pelvic inflammatory disease: the PID Evaluation and Clinical Health (PEACH) Study,” Sexually Transmitted Diseases, vol. 35, no. 2, pp. 129–135, 2008.

[28] D. Pietrella, L. Angioletta, E. Vavala et al., “Beneficial effect of Mentha suaveolens essential oil in the treatment of vaginal candidiasis assessed by real-time monitoring of infection,” BMC Complementary and Alternative Medicine, vol. 11, article 18, 2011.

[29] R. F. Nieuwenhuis, J. M. Ossewaarde, H. M. Götz et al., “Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar L2 proctitis in The Netherlands among men who have sex with men,” Clinical Infectious Diseases, vol. 39, no. 7, pp. 996–1003, 2004.

[30] R. Martin-Iguacel, J. M. Llibre, H. Nielsen et al., “Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialised countries,” European Journal of Clinical Microbiology & Infectious Diseases, vol. 29, no. 8, pp. 917–925, 2010.

[31] J. Siemer, O. Theile, Y. Larbi et al., “Chlamydia trachomatis infection as a risk factor for infertility among women in Ghana, West Africa,” American Journal of Tropical Medicine and Hygiene, vol. 78, no. 2, pp. 323–327, 2008.

[32] R. Detels, A. M. Green, J. D. Klausner et al., “The incidence and correlates of symptomatic and asymptomatic chlamydia trachomatis and neisseria gonorrhoeae infections in selected populations in five countries,” Sexually Transmitted Diseases, vol. 38, no. 6, pp. 503–509, 2011.

[33] Centers for Disease Control, “Sexually transmitted diseases (STD) treatment guidelines,” Morbidity and Mortality Weekly Report, vol. 59, no. RR-12, pp. 79–85, 2010, http://www.cdc.gov/std/treatment/2010/STD-Treatment-2010-RR5912.pdf.

[34] P. B. Wyrick and S. T. Knight, “Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin,” Journal of Antimicrobial Chemotherapy, vol. 54, no. 1, pp. 79–85, 2004.
